Long-lasting immune activity in the airways might be the cause of persistent breathlessness following COVID-19.
A new study of 38 people who were previously hospitalized with severe COVID-19 suggests these patients have an altered landscape of immune cells in their airways and signs of ongoing lung damage.
The preliminary results hint that this might improve over time.
The researchers say that their findings need to be confirmed by a larger study, but suggest that recovery from COVID-19 might be accelerated by treatments that dampen the immune system and reduce inflammation.
“Our study found that many months after SARS-CoV-2 infection, there were still abnormal immune cells in the airways of patients with persistent breathlessness,” said joint lead author, Dr. James Harker, from Imperial’s National Heart & Lung Institute. “ We also identified a protein ‘signature’ in the lungs indicating ongoing injury to the airways.”
Professor Pallav Shah, also from Imperial’s National Heart & Lung Institute, noted that the persistent breathlessness “is being caused by failure to turn off the immune response, which leads to airway inflammation and injury. The next steps of our research will be to see if there are treatments that can reduce the immune activity and whether they help to reduce the persistent breathlessness some patients experience.”
Previous studies have examined the causes of post-COVID-19 breathlessness by looking at markers in the blood, but the new study looks directly at which immune cells are active in the lungs too.
The researchers studied CT scans of the lungs and how well the lungs functioned, as well as analyzing samples of fluid from within the lungs and blood samples to determine the presence of nearly 500 proteins.
Overall, the study included 38 post-COVID-19 patients three to six months after they left hospital and 29 healthy volunteers (who had no underlying diseases and had not had COVID-19) to compare against.
At three to six months, the researchers found that there were more immune cells in the lungs of the post-COVID-19 participants than in the healthy controls. However, there appeared to be no difference in the immune cells seen in the blood of the post-COVID-19 and the healthy participants.
Co-author, Dr Bavithra Vijayakumar, also from Imperial’s National Heart & Lung Institute, said: “Other research has found that the immediate response to COVID-19 involves an uptick in various types of immune cells in the blood and in the lungs to fight the virus. For severe infections, like those seen in our study participants, there also tends to be heightened signs of inflammation. However, after three to six months, it appears that these signs in the blood return to normal, while those in the lungs take longer to resolve. Our finding that the immune response in the blood doesn’t appear to match that of the lungs emphasizes the importance of assessing airway immunity in order to better understand persistent respiratory symptoms post COVID-19.”
Although the immune cells in the lungs varied for each post-COVID-19 patient, they all tended to have higher levels of immune cells linked to cell death, epithelial damage and tissue repair.
There also appeared to be distinct roles for the different immune cells in the lungs. For example, higher numbers of cytotoxic T cells led to damage to the lung tissue and greater airway dysfunction, while having more B cells was associated with greater signs of lung abnormalities on CT scans (such as scarring and physical changes in the lung tissue).
A group of 17 post-COVID-19 participants were re-assessed a year after they had left hospital, and 14 of them saw improvements in their symptoms and fewer lung abnormalities on CT scans. The other three participants still showed lung abnormalities on CT scans, but the numbers of immune cells present in their airways was greatly reduced compared to their earlier assessments. The researchers say that this suggests that these immune responses may improve over time.
The authors note that their study includes patients who had severe COVID-19 disease (requiring hospitalization and ongoing monitoring) and it is unclear if their results would apply to people with less severe disease. They were only able to study the participants’ lungs after COVID-19, and so are unable to determine if any of the signs they discovered were present before infection.
They note that the participants of their study had COVID-19 before vaccines were available.
The study was funded by the Wellcome Trust, with staff supported by the UKRI, CW+ and the Westminster Medical School Research Trust, Asthma UK, Community Jameel and the Imperial College London President’s excellence fund. The study included collaborators from the National Heart and Lung Institute and the Department of Immunology and Inflammation at Imperial College London, Chelsea and Westminster Hospital, Royal Brompton and Harefield Hospitals and the Asthma UK Centre for Allergic Mechanisms of Asthma.
Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity, 25 January 2022.